- Title
- Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows
- Creator
- Regan, Megan; Fleming, Gini; Walley, Barbara; Francis, Prudence; Pagani, Olivia
- Relation
- NHMRC.351161 http://purl.org/au-research/grants/nhmrc/351161
- Relation
- Journal of Clinical Oncology Vol. 37, Issue 11, p. 862-867
- Publisher Link
- http://dx.doi.org/10.1200/JCO.18.02433
- Publisher
- American Society of Clinical Oncology
- Resource Type
- journal article
- Date
- 2019
- Description
- Research has shown premenopausal women with hormone receptor–positive (HR+) early breast cancer who experience chemotherapy-induced amenorrhea (CIA) have reduced risk of recurrence compared with those who have no CIA, whether treated with adjuvant chemotherapy alone or followed by tamoxifen. Younger premenopausal women, in particular those younger than 35 years, are less likely to experience CIA and have increased risk of recurrence. The Suppression of Ovarian Function Trial (SOFT) tested whether women with HR+ breast cancer who remained premenopausal after chemotherapy, and those never receiving chemotherapy, benefit from adding ovarian function suppression (OFS) to 5 years of tamoxifen treatment, or from use of the aromatase inhibitor (AI) exemestane with OFS. The companion Tamoxifen and Exemestane Trial (TEXT) tested the benefit of exemestane versus tamoxifen for women receiving adjuvant OFS, with or without chemotherapy.
- Subject
- premenopausal women; breast cancer; chemotherapy-induced amenorrhea (CIA); hormone receptor–positive (HR+) early breast cancer
- Identifier
- http://hdl.handle.net/1959.13/1400525
- Identifier
- uon:34779
- Identifier
- ISSN:1527-7755
- Language
- eng
- Full Text
- Reviewed
- Hits: 11893
- Visitors: 3774
- Downloads: 223
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 566 KB | Adobe Acrobat PDF | View Details Download |